Histological evolution of hepatitis C virus infection after renal transplantation
Background information regarding histological progression of hepatitis C after renal transplant (RTx) is scarce. Aims To analyze clinical and laboratory evolution and histological progression of hepatitis C in patients evaluated before and after RTx. Methods Twenty‐two HCV‐infected patients submitte...
Saved in:
Published in: | Clinical transplantation Vol. 26; no. 6; pp. 842 - 848 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Hoboken, NJ
Blackwell Publishing Ltd
01-11-2012
Wiley |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background
information regarding histological progression of hepatitis C after renal transplant (RTx) is scarce.
Aims
To analyze clinical and laboratory evolution and histological progression of hepatitis C in patients evaluated before and after RTx.
Methods
Twenty‐two HCV‐infected patients submitted to liver biopsy pre‐ and post‐RTx were included. A semiquantitative analysis of necroinflammatory activity and fibrosis staging was performed and the two biopsies were compared.
Results
Patients were mostly men (73%) with mean age of 36 ± 9 yr. Time post‐transplant was 4 ± 2 yr and time between biopsies was 5 ± 2 yr. An elevation of alanine aminotransferase (p = 0.041) and aspartate aminotransferase (p = 0.004) levels was observed in the post‐transplant period. Fibrosis progression after renal transplantation was observed in 11 (50%) of the patients, and necroinflammatory activity worsening was observed in 7 (32%) of the patients. The histological progression occurred even among those without significant histological lesions in pre‐transplant biopsy.
Conclusion
The findings of this study suggest that the practice of indicating treatment in the pre‐transplant phase based mainly on histological disease should be revised, because a high proportion of patients present disease progression. Because interferon cannot be used safely after RTx, treatment should be indicated for all ESRD patients with hepatitis C. |
---|---|
Bibliography: | ark:/67375/WNG-LBKVLPDK-K ArticleID:CTR1635 istex:423A7A816C9B8A7B0FB504AB88D2CAD5AB064691 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
ISSN: | 0902-0063 1399-0012 |
DOI: | 10.1111/j.1399-0012.2012.01635.x |